TriaGen Wealth Management’s Biogen BIIB Stock Holding History

TriaGen Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,536	Closed	-$702K	–	161
2022 Q4	$702K	Buy	+2,536	New	+$716K	0.39%	70

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TriaGen Wealth Management's BIIB Position: Q1 2023 in Review

TriaGen Wealth Management sold out of Biogen (BIIB) in Q1 2023, closing a stake of 2,536 shares — an estimated $702K sold.

TriaGen Wealth Management first reported a position in BIIB in Q4 2022 and held it in 1 quarter. The position peaked at $702K in Q4 2022. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

TriaGen Wealth Management reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
TriaGen Wealth Management sold 2,536 Biogen shares in Q1 2023, an estimated $702K.
TriaGen Wealth Management first reported a position in Biogen in Q4 2022 and held it in 1 quarter.
TriaGen Wealth Management's Biogen position peaked at $702K in Q4 2022.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on TriaGen Wealth Management's 13F filing for Q1 2023, filed 24 Apr 2023.